June 17th, 2016
Episode 1028 of 1744 episodes
Over 2700 people in England may be affected if health watchdog NICE decide not to approve a "breakthrough" treatment for people with cystic fibrosis for use on the NHS. The drug Orkambi, which costs 104,000 a year per patient, has been shown to improve lung function and respiratory symptoms in people with cystic fibrosis, but NICE said the benefits were modest. Fourteen-year-old Clara Mann, who has cystic fibrosis, and her father Nicholas Mann discuss the benefits the drug has had on her life. (Image: Child with nurse. Credit: SPL)
Welcome to the Brain Training Podcast, the daily audio workout for your head. In this podcast we have two games for you, each with three rounds which get progressively harder. To enjoy the full experience, relax, and avoid distractions whilst you listen.